Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 12th Congress of the European Academy of Neurology (EAN) is currently taking place in Geneva, Switzerland. This meeting is one of Europe’s biggest forums for neurology, bringing together experts to share the latest research across a variety of diseases.

EAN 2026

The 12th Congress of the European Academy of Neurology
27–30 June 2026 | Geneva, Switzerland

EAN 2026

The 12th Congress of the European Academy of Neurology
27–30 June 2026 | Geneva, Switzerland
The 12th Congress of the European Academy of Neurology (EAN) is currently taking place in Geneva, Switzerland. This meeting is one of Europe’s biggest forums for neurology, bringing together experts to share the latest research across a variety of diseases.
Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial 3:58
Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial
Richard Nowak • 24 Jun 2026
One big question with Dr Richard Nowak: what MG advance could transform care in the next 3 years? 2:07
One big question with Dr Richard Nowak: what MG advance could transform care in the next 3 years?
Richard Nowak • 28 Jun 2026
The potential value of broad rim lesions in the understanding and management of multiple sclerosis 1:02
The potential value of broad rim lesions in the understanding and management of multiple sclerosis
Joost Smolders • 27 Jun 2026
What is currently known about broad rim lesions in multiple sclerosis? 1:19
What is currently known about broad rim lesions in multiple sclerosis?
Joost Smolders • 27 Jun 2026
The evolving treatment landscape for myasthenia gravis and emerging approaches on the horizon 4:03
The evolving treatment landscape for myasthenia gravis and emerging approaches on the horizon
Richard Nowak • 27 Jun 2026
Optimizing outcomes for patients with migraine who have a partial response to eptinezumab 2:16
Optimizing outcomes for patients with migraine who have a partial response to eptinezumab
Alessandro Visentini • 27 Jun 2026
PACAP-38 is increased in the tear fluid of patients with migraine 1:50
PACAP-38 is increased in the tear fluid of patients with migraine
Marina Romozzi • 27 Jun 2026
Current limits of L-DOPA therapy in PD and approaches to optimization 1:19
Current limits of L-DOPA therapy in PD and approaches to optimization
Francesca Morgante • 27 Jun 2026
One big question with Francesca Morgante: what PD advance could transform care in the next 3 years? 1:44
One big question with Francesca Morgante: what PD advance could transform care in the next 3 years?
Francesca Morgante • 27 Jun 2026
The content of VJNeurology is intended for healthcare professionals